首页 | 本学科首页   官方微博 | 高级检索  
     

c-Met活化与肺癌的关系及其靶向药物的研究进展
引用本文:曹旭,杨洋,孙也淇,陈岗. c-Met活化与肺癌的关系及其靶向药物的研究进展[J]. 第二军医大学学报, 2013, 34(5): 557-560
作者姓名:曹旭  杨洋  孙也淇  陈岗
作者单位:1. 同济大学医学院附属上海市肺科医院病理科,上海,200433
2. 同济大学医学院附属上海市肺科医院胸外科,上海,200433
摘    要:c-Met为酪氨酸激酶受体的一种,肝细胞生长因子(HGF)为其天然配体。c-Met的激活主要有HGF配体依赖型和非HGF配体依赖型两种形式。许多恶性肿瘤包括肺癌中存在c-Met的多种活化机制,c-Met的异常激活亦与肺癌的发生发展及恶性生物学行为关系密切。本文就c-Met的活化与非小细胞肺癌及小细胞肺癌的关系及其靶向药物在肺癌中的研究进展作一综述。

关 键 词:原癌基因蛋白质c-Met  肺肿瘤  靶向治疗
收稿时间:2013-03-17
修稿时间:2013-04-19

Abnormal activation of c-Met in lung cancer and research progress of the targeted drugs: a review
CAO Xu,YANG Yang,SUN Ye-qi and CHEN Gang. Abnormal activation of c-Met in lung cancer and research progress of the targeted drugs: a review[J]. Former Academic Journal of Second Military Medical University, 2013, 34(5): 557-560
Authors:CAO Xu  YANG Yang  SUN Ye-qi  CHEN Gang
Affiliation:1. Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China2. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China*Corresponding author.
Abstract:c-Met is a receptor tyrosine kinase (RTK) with hepatocyte growth factor (HGF) as its natural ligand. c-Met may be activated in a ligand-dependent manner by binding HGF or in a ligand-independent manner. Diverse activation mechanisms of c-Met exist in many malignant tumors, including lung cancer. Moreover, the abnormal activation of c-Met has a close relationship with the occurrence, development and malignant biological behavior of lung cancer. This paper focused on the different activation mechanisms of c-Met in non-small cell lung cancer and small cell lung cancer and also reviewed the research progress of c-Met targeted drugs in lung cancer.
Keywords:proto-oncogene proteins c-Met   lung neoplasms   targeted therapy
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《第二军医大学学报》浏览原始摘要信息
点击此处可从《第二军医大学学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号